Acquired factor VIII inhibitors in non-haemophilic patients: Clinical experience of 15 cases

Haemophilia

Volumn 10, Issue 6, 2004, Pages 713-721

  Huang, Yi Wu ^a,b   Saidi, P ^a   Philipp, C ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Acquired factor VIII inhibitor; Acquired haemophilia; Autoimmune disorder; Immunosuppressive therapy

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DESMOPRESSIN; DEXAMETHASONE; FLUPHENAZINE; IMMUNOGLOBULIN; PREDNISONE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RITUXIMAB; VINCRISTINE;

ACQUIRED BLOOD CLOTTING FACTOR 8 INHIBITOR; ACQUIRED HEMOPHILIA A; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEMARTHROSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG ASPERGILLOSIS; MALE; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; REMISSION; RETROSPECTIVE STUDY; SKIN BLEEDING; SOFT TISSUE; STEROID THERAPY; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; CYCLOPHOSPHAMIDE; DRUG COMBINATIONS; FACTOR VIII; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HEMORRHAGE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 11144254019     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2004.01031.x     Document Type: Article

References (37)

1. Kessler CM, Ludlam CA. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrates. Semin Hematol 1993; 30 (Suppl. I): 22-7.
2. Shapiro SS, Rajagopalan V. Hemorrhagic disorders associated circulating inhibitors. In: Ratnoff OD, Forbes CD, eds. Disorders of Hemostasis. Philadelphia, PA: WB Saunders Company, 1996: P208-27.
3. The UK Haemophilia Centre Doctors' Organization (UKHCDO). The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UKHCDO. Br J Haematol 2000; 111: 78-90.
4. Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-81.
5. Coots MC, Glueck HI. An acquired inhibitor to factor VIII:C in a nonhemophiliac: twenty years of observation and characterization. Am J Hematol 1987; 24: 415-24.
6. Green D. Cytotoxic suppression of acquired factor VIII:C inhibitors. Am J Med 1991; 91: 14S-9S.
7. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
8. Bossi P, Cabane J, Ninet J et al. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105 400-8.
9. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gamma-globulin. Blood 1995; 86: 797-804.
10. Negrier C, Goudemand J, Sultan Y et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
11. Bayer RL, Lichtman SM, Allen SL et al. Acquired factor VIII inhibitors: successful treatment with an oral outpatient regimen. Am J Hematol 1999; 60: 70-1.
12. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997; 78: 1463-7.
13. Lusher JM. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition. Am J Med 1991; 91: 30S-4S.
14. Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995; 73: 1-5.
15. Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisome and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-7.
16. Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired FVIII:C inhibitors. Br J Haematol 1981; 48: 635-42.
17. Green D. Immunosuppression of factor VIII inhibitors in non-hemophilic patients. Semin Hematol 1993; 30 (2Suppl. 1 : 28-31.
18. Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood 2003; 101: 943-5.
19. Kasper CK, Aledort L, Aronson D et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
20. Kessler CM. An introduction to factor VIII inhibitors: the detection and quantitation. Am J Med 1991; 91 (Suppl. 5A): 1S-5S.
21. Lian EC, Larcada AF, Chiu AY. Combination immunosuppresive therapy after factor VIIII infusion for acquired factor VIIII inhibitor. Ann Intern Med 1989; 110: 774-8.
22. Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated auto-antibodies. A prevalence study. Biol Psychol 1990; 27: 863-70.
23. Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for anti-phospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol 1990; 93: 771-5.
24. Green D, Schuette PT, Wallace WH. Factor VIII anti-bodies in rheumatoid arthritis: effect of cyclophosphamide. Arch Intern Med 1980; 140: 1232-5.
25. Hay CR, Lozier JN, Lee CA et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-9.
26. Morrison AE, Ludlam CA, Kessler C. Use of procine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993; 81: 1513-20.
27. de la Fuente B, Panek S, Hoyer LW. The effect of 1-deamino 8 D-arginine vasopressin (DDAVP) in a non-hemophilic patient with an acquired type II factor VIII inhibitors. Br J Haematol 1985; 59 127-31.
28. Feinstein DI. Inhibitors of blood coagulation. In: Hoffman R, Benz EJ, Cohen HJ, Silberstein LE, McGlave P., eds. Hematology: Basic Principles and Practice, 3rd edn. New York: Churchill Livingstone, 2000: 1963-82.
29. Glazer S, Hedner U, Falch JF. Clinical aspect on the use of recombinant factor VIIa. In: Aledort LM, Hoyer LW, Reisner HM, Whitell GC, Lusher JM., eds. Inhibitors to Coagulation Factors. New York: Pleum, 1996: 163.
30. Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use. Thromb Haemost 1996; 76: 200-4.
31. Santagostino E, Morfini M, Rocino A, Baudo F, Scaraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001; 86 954-8.
32. Narukawa N, Abe T, Shouno M et al. A case of factor VIII inhibitor-positive acquired hemophilia treated by plasmapheresis. Ther Apheresis 1999; 3: 323-5.
33. Jansen M, Schmaldienst S, Banyai S et al. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001; 112: 91-7.
34. Sultan Y, Kazatchkine M, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneous acquired factor VIII:C inhibitors. Am J Med 1991; 91: 35S-9S.
35. Frommel D. Anti-idiotypic suppression of antibodies to factor VIIIc. Lancet 1984; 2: 1210-1.
36. Tiarks C, Pechet L, Humphreys RE. Development of anti-idiotypic antibodies in a patient with a factor VIII antoantibody. Am J Hematol 1989; 32: 217-21.
37. Escobar M, Kempton C, Ma A. Successful treatment of an autoantibody in congenital hemophilia with rituximab. Blood 2002; 16: 109b.